Similar articles

• Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6-8 October, 2000.

  Cartwright K, Noah N, Peltola H; Meningococcal Disease Advisory Board. Cartwright K, et al. Vaccine. 2001 Aug 14;19(31):4347-56. doi: 10.1016/s0264-410x(01)00205-5. Vaccine. 2001. PMID: 11534497 No abstract available.
• [Meningococcal vaccines: from polysaccharide to conjugate vaccines].

  Cohen R, Levy C. Cohen R, et al. Arch Pediatr. 2012 Sep;19 Suppl 2:S61-4. doi: 10.1016/S0929-693X(12)71275-7. Arch Pediatr. 2012. PMID: 22883368 French.
• Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines.

  Trotter CL, Ramsay ME. Trotter CL, et al. FEMS Microbiol Rev. 2007 Jan;31(1):101-7. doi: 10.1111/j.1574-6976.2006.00053.x. Epub 2006 Dec 1. FEMS Microbiol Rev. 2007. PMID: 17168998
• 2010 FIFA world cup South Africa: travel health issues and new options for protection against meningococcal disease.

  Zuckerman JN, Bröker M, Worth C. Zuckerman JN, et al. Travel Med Infect Dis. 2010 Mar;8(2):68-73. doi: 10.1016/j.tmaid.2010.04.004. Travel Med Infect Dis. 2010. PMID: 20478511 Review.
• Vaccines against meningococcal disease: current and future technologies.

  Riddell A, Buttery J. Riddell A, et al. Expert Opin Biol Ther. 2001 May;1(3):385-99. doi: 10.1517/14712598.1.3.385. Expert Opin Biol Ther. 2001. PMID: 11727513 Review.